The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
The role of the LRRK2 gene in Parkinsonism
Open accessAbstract
Parkinson's disease (PD), like many common age-related conditions, has been recognized to have a substantial genetic component. Multiple lines of evidence suggest that Leucine-rich repeat kinase 2 (LRRK2) is a crucial factor to understanding the etiology of PD. LRRK2 is a large, widely expressed, multi-domain and multifunctional protein. LRRK2 mutations are the major cause to inherited and sporadic PD. In this review, we discuss the pathology and clinical features which show diversity and variability of LRRK2-associated PD. In addition, we do a thorough literature review and provide theoretical data for gene counseling. Further, we present the evidence linking LRRK2 to various possible pathogenic mechanism of PD such as α-synuclein, tau, inflammatory response, oxidative stress, mitochondrial dysfunction, synaptic dysfunction as well as autophagy-lysosomal system. Based on the above work, we investigate activities both within GTPase and outside enzymatic regions in order to obtain a potential therapeutic approach to solve the LRRK2 problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is characterized by filamentous and oligomeric 𝛂 -synuclein ( 𝛂 -syn) accumulation, and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) leading to motor impairments (357, 616).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [357]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The most common LRRK2 mutation, G2019S (gain of function), is associated with 2% of sporadic cases and 6% of familial cases (357).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [357]
In the citing paper
“LRRK2 (PARK8) gene mutations are the most common genetic cause of both familial and sporadic PD.257”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Lysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,807
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Inhibition of Macroautophagy Triggers Apoptosis
Boya, P., González‐Polo, R. A., Casares, N., Perfettini, J., Dessen, P., Larochette, N., Métivier, D., Meley, D., Souquère, S., Yoshimori, T., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.3.1025-1040.2005 · Cited by 1,669
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Cited by
Sorted by citations
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Brain-Gut-Microbiota Axis in Parkinson’s Disease
Mulak, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10609 · Cited by 583
Autophagy in Parkinson's Disease
Hou, X., Watzlawik, J. O., Fiesel, F. C., & Springer, W. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.037 · Cited by 361
Alpha-Synuclein Aggregation in Parkinson's Disease
Srinivasan, E., Chandrasekhar, G., Chandrasekar, P., Anbarasu, K., Vickram, A. S., Karunakaran, R., Rajasekaran, R., & Srikumar, P. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.736978 · Cited by 271
Autophagy, aging, and age-related neurodegeneration
Palmer, J. E., Wilson, N., Son, S. M., Obrocki, P., Wróbel, L., Rob, M., Takla, M., Korolchuk, V. I., & Rubinsztein, D. C. (2024) · Neuron · doi:10.1016/j.neuron.2024.09.015 · Cited by 277
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
Leggio, L., Vivarelli, S., L’Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Marchetti, B., & Iraci, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122698 · Cited by 218
Parkinson's disease: Cause factors, measurable indicators, and early diagnosis
Bhat, S., Acharya, U. R., Hagiwara, Y., Dadmehr, N., & Adeli, H. (2018) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2018.09.008 · Cited by 211
Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., Chou, M.-Y., Howden, A. J. M., König, T., Hotzy, C., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180248 · Cited by 222
Ysselstein, D., Nguyen, M. N., Young, T. J., Severino, A., Schwake, M., Merchant, K., & Krainc, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13413-w · Cited by 193
The impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185
Brain Disorders Due to Lysosomal Dysfunction
Fraldi, A., Klein, A. D., Medina, D. L., & Settembre, C. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014031 · Cited by 173
Early synaptic dysfunction in Parkinson's disease: Insights from animal models
Schirinzi, T., Madeo, G., Martella, G., Maltese, M., Picconi, B., Calabresi, P., & Pisani, A. (2016) · Movement Disorders · doi:10.1002/mds.26620 · Cited by 163
Recent Advances in Pyrimidine-Based Drugs
Nammalwar, B., & Bunce, R. A. (2024) · Pharmaceuticals · doi:10.3390/ph17010104 · Cited by 171
Lin, K.-J., Lin, K.-L., Chen, S., Liou, C., Chuang, Y., Lin, H., & Lin, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215312 · Cited by 141
Zebrafish as a model organism for neurodegenerative disease
Chia, K., Klingseisen, A., Sieger, D., & Priller, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.940484 · Cited by 138
Alajangi, H. K., Kaur, M., Sharma, A., Rana, S., Thakur, S., Chatterjee, M., Singla, N., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00937-4 · Cited by 137
Early Life Stress, Depression And Parkinson’s Disease: A New Approach
Dallé, E., & Mabandla, M. V. (2018) · Molecular Brain · doi:10.1186/s13041-018-0356-9 · Cited by 131
Mitophagy and reactive oxygen species interplay in Parkinson’s disease
Xiao, B., Kuruvilla, J., & Tan, E. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00402-y · Cited by 117
The associations between Parkinson’s disease and cancer: the plot thickens
Feng, D. D., Cai, W., & Chen, X. M. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0043-z · Cited by 103
Autophagy in Parkinson’s Disease
Nechushtai, L., Frenkel, D., & Pinkas‐Kramarski, R. (2023) · Biomolecules · doi:10.3390/biom13101435 · Cited by 109
Vanda, D., Zajdel, P., & Soural, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111569 · Cited by 98
Rab GTPases: Switching to Human Diseases
Guadagno, N. A., & Progida, C. (2019) · Cells · doi:10.3390/cells8080909 · Cited by 97
Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases
Fernández‐Moriano, C., González‐Burgos, E., & Gómez-Serranillos, M. P. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/408927 · Cited by 100
Calabrese, G., Molzahn, C. M., & Mayor, T. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102062 · Cited by 92
Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis
Jiang, L., Zhang, H., Wang, C., Ming, F., Shi, X., & Yang, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.07.010 · Cited by 88
Wang, C., Yang, T., Liang, M., Xie, J., & Song, N. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00265-y · Cited by 90
Ludtmann, M. H. R., Kostić, M., Horne, A., Gandhi, S., Sekler, I., & Abramov, A. Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1469-5 · Cited by 83
Krauskopf, J., Caiment, F., van Veldhoven, K., Chadeau‐Hyam, M., Sinharay, R., Chung, K. F., Cullinan, P., Collins, P. D., Barratt, B., Kelly, F. J., et al. (2018) · Environment International · doi:10.1016/j.envint.2018.01.014 · Cited by 83
S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation
Kumar, R., Jangir, D. K., Verma, G., Shekhar, S., Hanpude, P., Kumar, S., Kumari, R., Singh, N., Bhavesh, N. S., Jana, N. R., et al. (2017) · Scientific Reports · doi:10.1038/srep44558 · Cited by 83
Parkinson’s disease detection and classification using EEG based on deep CNN-LSTM model
Li, K., Ao, B., Wu, X., Wen, Q., Haq, E. U., & Yin, J. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2200333 · Cited by 82
CHCHD2 gene mutations in familial and sporadic Parkinson's disease
Shi, C., Mao, C., Zhang, S., Yang, J., Song, B., Wu, P., Zuo, C., Liu, Y., Ji, Y., Yang, Z.-H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.040 · Cited by 81
Qing, X., Walter, J., Jarazo, J., Arias, J., Hillje, A., & Schwamborn, J. C. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.08.013 · Cited by 74
Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders
Pardo, A. D., & Maglione, V. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00249 · Cited by 75
Regulation of autophagy by polyphenols: Paving the road for treatment of neurodegeneration
Nabavi, S. F., Sureda, A., Dehpour, A. R., Shirooie, S., Sanches-Silva, A. T., Devi, K. P., Ahmed, T., Ishaq, N., Hashim, R., Sobarzo‐Sánchez, E., et al. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.12.001 · Cited by 74
Role of 5-hydroxymethylcytosine in neurodegeneration
Sherwani, S. I., & Khan, H. A. (2015) · Gene · doi:10.1016/j.gene.2015.06.052 · Cited by 70
Mohammadi, S., Dolatshahi, M., & Rahmani, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01314-5 · Cited by 65
Wang, X., Feng, S., Wang, Y., Yuan, Y., Li, Z., Chen, N., Wang, Z., & Zhang, Y. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01039-w · Cited by 66
α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities
Lööv, C., Scherzer, C. R., Hyman, B. T., Breakefield, X. O., & Ingelsson, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0317-0 · Cited by 68
LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
Wojewska, D., & Kortholt, A. (2021) · Biomolecules · doi:10.3390/biom11081101 · Cited by 64
Pierce, S. E., & Coetzee, G. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175882 · Cited by 64
Wang, Y.-T., & Lu, J. (2022) · Cells · doi:10.3390/cells11142250 · Cited by 62
Structure-based prediction of ligand–protein interactions on a genome-wide scale
Hwang, H., Dey, F., Petrey, D. S., & Honig, B. H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705381114 · Cited by 59
Centrality of Early Synaptopathy in Parkinson’s Disease
Imbriani, P., Schirinzi, T., Meringolo, M., Mercuri, N. B., & Pisani, A. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00103 · Cited by 59
Circulating Inflammatory miRNAs Associated with Parkinson’s Disease Pathophysiology
Oliveira, S. R., Dionísio, P. A., Guedes, L. C., Gonçalves, N., Coelho, M. M., Rosa, M. M., Amaral, J. D., Ferreira, J. J., & Rodrigues, C. M. P. (2020) · Biomolecules · doi:10.3390/biom10060945 · Cited by 59
Stern, S., Lau, S., Manole, A., Rosh, I., Percia, M. M., Ezer, R. B., Shokhirev, M. N., Qiu, F., Schafer, S. T., Mansour, A. A., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00366-z · Cited by 60
The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
Polissidis, A., Petropoulou-Vathi, L., Nakos‐Bimpos, M., & Rideout, H. J. (2020) · Biomolecules · doi:10.3390/biom10060912 · Cited by 61
MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease
Arshad, A. R., Sulaiman, S. A., Saperi, A. A., Jamal, R., Ibrahim, N. M., & Murad, N. A. A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00352 · Cited by 54
Proteostasis of α-Synuclein and Its Role in the Pathogenesis of Parkinson’s Disease
Han, D., Zheng, W., Wang, X., & Chen, Z. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00045 · Cited by 55
Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
Liu, H., Ho, P. W., Leung, G. C.-T., Lam, C. S.-C., Pang, S. Y.-Y., Li, L., Kung, M. H.-W., Ramsden, D. B., & Ho, S. (2017) · Scientific Reports · doi:10.1038/srep40887 · Cited by 55
Vacchi, E., Kaelin‐Lang, A., & Melli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145030 · Cited by 51
Dhanwani, R., Lima-Júnior, J. R., Sethi, A., Pham, J. W., Williams, G. P., Frazier, A., Xu, Y., Amara, A. W., Standaert, D. G., Goldman, J. G., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00282-2 · Cited by 53
Wang, X., Negrou, E., Maloney, M. T., Bondar, V. V., Andrews, S. V., Montalban, M., Llapashtica, C., Maciuca, R. D., Nguyen, H. N., Solanoy, H. O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91943-4 · Cited by 50
Fifty-Hertz Magnetic Field Affects the Epigenetic Modulation of the miR-34b/c in Neuronal Cells
Consales, C., Cirotti, C., Filomeni, G., Panatta, M., Butera, A., Merla, C., Lopresto, V., Pinto, R., Marino, C., & Benassi, B. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0791-0 · Cited by 49
Bhurane, A. A., Dhok, S. G., Sharma, M. D., Yuvaraj, R., Murugappan, M., & Acharya, U. R. (2019) · Expert Systems · doi:10.1111/exsy.12472 · Cited by 47
Yang, K., Zeng, L., Zeng, J., Deng, Y., Wang, S., Xu, H., He, Q., Yuan, M., Luo, Y., Ge, A., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102063 · Cited by 46
Karthivashan, G., Ganesan, P., Park, S., Lee, H., & Choi, D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119704 · Cited by 47
Gan, H. K., Zhang, L., Chen, H., Xiao, H., Wang, L., Zhai, X., Jiang, N., Liang, P., Zheng, S., & Zhao, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00702-y · Cited by 48
Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders
Kay, L., Pienaar, I. S., Cooray, R., Black, G. W., & Soundararajan, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0927-x · Cited by 44
Emerging roles of the αC‐β4 loop in protein kinase structure, function, evolution, and disease
Yeung, W., Ruan, Z., & Kannan, N. (2020) · IUBMB Life · doi:10.1002/iub.2253 · Cited by 39
Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders
Hanif, S., Muhammad, P., Niu, Z., Ismail, M., Morsch, M., Zhang, X., Li, M., & Shi, B. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100008 · Cited by 44
Chen, M., & Wu, R. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0454-0 · Cited by 42
Rab GTPases as Physiological Substrates of LRRK2 Kinase
Seol, W., Nam, D., & Son, I. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.2.134 · Cited by 42
Price, A., Manzoni, C., Cookson, M. R., & Lewis, P. A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2759-9 · Cited by 39
Chernivec, E., Cooper, J. T., & Naylor, K. (2018) · Cells · doi:10.3390/cells7110201 · Cited by 43
Exploring the Role of Autophagy Dysfunction in Neurodegenerative Disorders
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Bhatia, S., Al‐Harrasi, A., & BUNGAU, S. G. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02472-0 · Cited by 42
Comprehensive Perspectives on Experimental Models for Parkinson’s Disease
Ke, M., Chong, C., Zhu, Q., Zhang, K., Cai, C.-Z., Lu, J., Qin, D., & Su, H. (2021) · Aging and Disease · doi:10.14336/ad.2020.0331 · Cited by 41
Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained Peptides
Helton, L. G., Soliman, A., von Zweydorf, F., Kentros, M., Manschwetus, J. T., Hall, S., Gilsbach, B. K., Ho, F. Y., Athanasopoulos, P. S., Singh, R. K., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00487 · Cited by 38
Yaribash, S., Mohammadi, K., & Sani, M. A. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01544-2 · Cited by 44
Lee, S. J. Y., Ng, J. H., Saffari, S. E., & Tan, E. (2022) · Aging · doi:10.18632/aging.203932 · Cited by 38
Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson’s Disease
Johnson, W. M., Golczak, M., Choe, K., Curran, P. L., Miller, O. G., Yao, C., Wang, W., Lin, J., Milkovic, N. M., Ray, A., et al. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01132 · Cited by 37
Analyzing and Visualizing Genomic Complexity for the Derivation of the Emergent Molecular Networks
Koutsandreas, T., Binenbaum, I., Pilalis, E. D., Valavanis, I. K., Papadodima, O., & Chatziioannou, A. A. (2016) · International Journal of Monitoring and Surveillance Technologies Research · doi:10.4018/ijmstr.2016040103 · Cited by 37
Golgi Complex Dynamics and Its Implication in Prevalent Neurological Disorders
Caracci, M. O., Fuentealba, L. M., & Marzolo, M. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00075 · Cited by 39
D’Souza, T., & Rajkumar, A. P. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.28 · Cited by 37
G2385R and I2020T Mutations Increase LRRK2 GTPase Activity
Ho, D. H., Jang, J., Joe, E.-H., Son, I., Seo, H., & Seol, W. (2016) · BioMed Research International · doi:10.1155/2016/7917128 · Cited by 37
Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein
Mansour, H. M., & El-Khatib, A. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102114 · Cited by 36
Salado, I. G., Zaldívar-Díez, J., Sebastián-Pérez, V., Li, L., Geiger, L., González, S., Campillo, N. E., Gil, C., Morales, A. V., Pérez, D. I., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.060 · Cited by 36
Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Rane, P., Sarmah, D., Bhute, S., Kaur, H., Goswami, A., Kalia, K., Borah, A., Dave, K. R., Sharma, N., & Bhattacharya, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00180 · Cited by 35
Agrahari, A. K., Doss, C. G. P., Ramamoorthy, S., Magesh, R., & Zayed, H. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.03.003 · Cited by 36
The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation
Bae, E.-J., & Lee, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165632 · Cited by 34
Vesicular Dysfunction and the Pathogenesis of Parkinson’s Disease: Clues From Genetic Studies
Ebanks, K., Lewis, P. A., & Bandopadhyay, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01381 · Cited by 38
Promising Targets for the Treatment of Neurodegenerative Diseases
Haeberlein, S. B., & Harris, T. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.195 · Cited by 35
The MicroRNA Centrism in the Orchestration of Neuroinflammation in Neurodegenerative Diseases
Nuzziello, N., & Liguori, M. (2019) · Cells · doi:10.3390/cells8101193 · Cited by 36
Kumari, R., Kumar, R., Kumar, S., Singh, A. K., Hanpude, P., Jangir, D. K., & Maiti, T. K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009546 · Cited by 36
LRRK2 Structure-Based Activation Mechanism and Pathogenesis
Zhang, X., & Kortholt, A. (2023) · Biomolecules · doi:10.3390/biom13040612 · Cited by 34
Association of Parkinson’s Disease GWAS-Linked Loci with Alzheimer’s Disease in Han Chinese
Zhu, X., Cao, L., Tan, M., Jiang, T., Wang, H.-F., Lu, H., Tan, C., Zhang, W., Tan, L., & Yu, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9649-5 · Cited by 34
Self-citationIntegrated network analysis reveals new genes suggesting COVID-19 chronic effects and treatment
Pavel, A., del Giudice, G., Federico, A., Lieto, A. D., Kinaret, P., Serra, A., & Greco, D. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa417 · Cited by 33
Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c09114 · Cited by 38
Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications
Ouerdane, Y., Hassaballah, M. Y., Nagah, A., Ibrahim, T. M., Mohamed, H. A. H., El-Baz, A., & Attia, M. S. (2022) · Pharmaceuticals · doi:10.3390/ph15010076 · Cited by 31
Marrone, L., Bus, C., Schöndorf, D. C., Fitzgerald, J. C., Kübler, M., Schmid, B., Reinhardt, P., Reinhardt, L., Deleidi, M., Levin, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192497 · Cited by 30
Genetic Modifiers in Neurodegeneration
Jain, N., & Chen‐Plotkin, A. S. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0133-1 · Cited by 34
Induced pluripotent stem cell‐based modeling of mutant LRRK 2‐associated Parkinson's disease
Weykopf, B., Haupt, S., Jungverdorben, J., Flitsch, L. J., Hebisch, M., Liu, G., Suzuki, K., Belmonte, J. C. I., Peitz, M., Blaess, S., et al. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14345 · Cited by 30
Funk, N., Munz, M., Ott, T., Brockmann, K., Wenninger-Weinzierl, A., Kühn, R., Weisenhorn, D. M. V., Giesert, F., Wurst, W., Gasser, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40808-y · Cited by 30
Neuronal microtubules and proteins linked to Parkinson’s disease: a relevant interaction?
Calogero, A. M., Mazzetti, S., Pezzoli, G., & Cappelletti, G. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0142 · Cited by 28
The Role of the Gut Microbiota in Neurodegenerative Diseases
Mani, A. P., Balasubramanian, B., Mali, L. A., Joseph, K. S., Meyyazhagan, A., Pappuswamy, M., & Joseph, B. V. (2024) · Microbiology Research · doi:10.3390/microbiolres15020033 · Cited by 37
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30
Behl, T., Madaan, P., Sehgal, A., Singh, S., Anwer, M. K., Makeen, H. A., Albratty, M., Mohan, S., & BUNGAU, S. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020678 · Cited by 27
The Endo-lysosomal System in Parkinson’s Disease: Expanding the Horizon
Muraleedharan, A., & Vanderperre, B. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168140 · Cited by 27
Zhou, L., Wang, Y., Xu, Y., Zhang, Y., & Zhu, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03232-2 · Cited by 26
Metadata
- Authors
- Li, J.-Q., Tan, L., & Yu, J.-T.
- Affiliations
- Qingdao University (CN)
- Corresponding author
- Tan, Lan
- Yu, Jin-Tai
- ORCID
- Venue
- Molecular Neurodegeneration
- Published
- 2014-11-12
- Volume
- 9
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC4246469
- OpenAlex
- W2145005920
- Cited by
- 249
- References
- 127
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 24 · 2023: 29 · 2022: 27 · 2021: 15 · 2020: 28 · 2019: 30 · 2018: 30 · 2017: 17 · 2016: 12 · 2015: 10
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81371406, ZR2011HZ001, 81171209, 81471309, ZR2010HQ004)
- Natural Science Foundation of Shandong Province (ZR2011HZ001, ZR2010HQ004)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- LRRK2, Parkinson's disease, leucine-rich repeat kinase 2, LRRK2 mutations, alpha-synuclein, tau protein, neuroinflammation, oxidative stress, mitochondrial dysfunction, synaptic dysfunction, autophagy-lysosome pathway, therapeutic target
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Animals, Humans, Protein Serine-Threonine Kinases, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review